This study states that Bladder cancer (BCa) accounts for ∼7% of all malignancies and represents a huge oncologic and economic burden.1 Around 25% to 30% of these patients present with muscle invasive bladder cancer (MIBC).2 Radical cystectomy (RC) with bilateral pelvic lymph node dissection (PLND), after neoadjuvant chemotherapy (NAC), is the standard of care for nonmetastatic MIBC and recurrent high-risk nonmuscle invasive bladder cancer (NMIBC).3 Open radical cystectomy (ORC) has been the most commonly used approach with robust data available on feasibility, complications, and oncologic outcomes. However, there is significant perioperative morbidity associated with ORC with 30- and 90-day overall Clavien–Dindo Classification (CDC) complication rates ranging from 30% to 60%. To circumvent some of the complications of this extensively extirpative surgery, minimally invasive RC was described. However, laparoscopic radical cystectomy (LRC) with PLND is a technically challenging procedure and large series have mainly been reported from high-volume centers with experienced surgeons. Although robotic radical cystectomy (RRC) remains a technically demanding surgery, the robotic system offers much better ergonomics and a shorter learning curve than LRC. Consequently, there have been numerous series reported for RRC worldwide.
Reference link- https://www.liebertpub.com/doi/10.1089/end.2020.0112
